Cellular Biomedicine Group Inc. , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced interim 24-week clinical data from the Phase IIb trial of its ReJoinTM human adipose-derived mesenchymal progenitor cell therapy for Knee Osteoarthritis . The data will be discussed by Dr. Wei Cao, PhD, BM, Chief Executive Officer of Cellular Biomedicine Group at the 2015 Annual Regen Med Investor Day at the Metropolitan Club in New York City.
http://ift.tt/1BmCEoj
http://ift.tt/1BmCEoj
No comments:
Post a Comment